PASG vs. CKPT, IPHA, ADAP, PBYI, BMEA, CDTX, FATE, RENB, STRO, and TCRX
Should you be buying Passage Bio stock or one of its competitors? The main competitors of Passage Bio include Checkpoint Therapeutics (CKPT), Innate Pharma (IPHA), Adaptimmune Therapeutics (ADAP), Puma Biotechnology (PBYI), Biomea Fusion (BMEA), Cidara Therapeutics (CDTX), Fate Therapeutics (FATE), Renovaro (RENB), Sutro Biopharma (STRO), and TScan Therapeutics (TCRX). These companies are all part of the "pharmaceutical products" industry.
Passage Bio vs.
Checkpoint Therapeutics (NASDAQ:CKPT) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.
Checkpoint Therapeutics has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500. Comparatively, Passage Bio has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500.
Checkpoint Therapeutics has higher revenue and earnings than Passage Bio. Checkpoint Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.
In the previous week, Passage Bio had 3 more articles in the media than Checkpoint Therapeutics. MarketBeat recorded 4 mentions for Passage Bio and 1 mentions for Checkpoint Therapeutics. Checkpoint Therapeutics' average media sentiment score of 0.28 beat Passage Bio's score of -0.17 indicating that Checkpoint Therapeutics is being referred to more favorably in the media.
22.0% of Checkpoint Therapeutics shares are owned by institutional investors. Comparatively, 53.5% of Passage Bio shares are owned by institutional investors. 2.1% of Checkpoint Therapeutics shares are owned by insiders. Comparatively, 4.3% of Passage Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Checkpoint Therapeutics received 128 more outperform votes than Passage Bio when rated by MarketBeat users. However, 68.42% of users gave Passage Bio an outperform vote while only 67.42% of users gave Checkpoint Therapeutics an outperform vote.
Checkpoint Therapeutics' return on equity of 0.00% beat Passage Bio's return on equity.
Checkpoint Therapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 277.36%. Passage Bio has a consensus target price of $7.75, suggesting a potential upside of 1,191.67%. Given Passage Bio's higher possible upside, analysts clearly believe Passage Bio is more favorable than Checkpoint Therapeutics.
Summary
Passage Bio beats Checkpoint Therapeutics on 9 of the 14 factors compared between the two stocks.
Get Passage Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for PASG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Passage Bio Competitors List
Related Companies and Tools
This page (NASDAQ:PASG) was last updated on 1/21/2025 by MarketBeat.com Staff
